Payer and Physician Receptivity to Oral HIF-PH Inhibitors and Other Novel Treatments: Which Emerging Drugs Excite Them?
Renal anemia is one of the primary complications of chronic kidney disease (CKD) and is treated with erythropoiesis-stimulating agents (ESAs) and oral/IV iron. The market for renal anemia drugs is poised to expand owing to the growing size of the CKD non-dialysis (CKD-ND) and dialysis patient populations as well as the expected launches of novel therapies such as oral hypoxia-inducible factor-prolyl hydroxylase inhibitors (HIF-PHis) to treat renal anemia (e.g., FibroGen/Astellas/AstraZeneca’s roxadustat, Akebia Therapeutics’ AKB-6548, GlaxoSmithKline’s daprodustat) and other new renal anemia treatments. Significant clinical and commercial opportunities remain for new renal anemia therapies that can provide improved effects on increasing hemoglobin, greater safety, and/or an improved delivery profile.
